Reporting from ESMO Congress 2019, Javier Cortes comments on positive studies in Breast Cancer that showed clinically relevant benefits. The results from MONALEESA-3 in HR+/HER2- postmenopausal breast cancer patients are further supportive for integration of CDK 4/6 inhibitors in combination with hormonal therapy in clinical practice. In early triple negative breast cancer (TNBC), KEYNOTE-522 demonstrated a benefit in response rate and showed a positive trend in terms of event-free survival with immunotherapy combined with chemotherapy in both neo-adjuvant and adjuvant treatments.
In KEYNOTE-119, in previously treated metastatic TNBC, immunotherapy alone wasn't better than chemotherapy, except in patients with PD-L1 overexpression, these finding will need to be confirmed.
Abstracts:
- LBA8_PR: KEYNOTE-522: Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
- LBA7_PR: Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
- LBA21: KEYNOTE-119: Phase 3 study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple-negative breast cancer (mTNBC)
This video was supported with an educational grant from Daiichi Sankyo and Novartis. The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.